These markers not only provide key prognostic information but increasingly determine eligibility for targeted agents (like eprenetapopt for TP53-mutant MDS; luspatercept for SF3B1-mutant MDS) and guide rational therapeutic combinations. Here, TP53 is linked to myelodysplastic syndrome.